- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
* Lumiphore technology to be used in diagnostic tests from Brahms AG and its subsidiary Cezanne
* High sensitivity, easy to use, minimal costs for materials
Lumiphore Inc., a leading California biotechnology company partly owned by Germany's Nanostart AG, has entered into an important new partnership agreement with Brahms AG, a Berlin-based diagnostics company and its French subsidiary Cezanne involving the use of its Lumi4®-Tb technology in diagnostic tests from Brahms.
Under the agreement, Brahms together with its subsidiary Cezanne has the non-exclusive rights to incorporate Lumi4® technology into current and future diagnostic tests and the exclusive rights to use the technology in diagnostic tests for Down's Syndrome including Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism.
"Lumiphore's goal is to bring the benefits of lanthanide-based homogenous assays to the diagnostic markets, from central labs to point-of-care applications. Detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore's new reporter technology," said Steve Blose, Chief Business Development Officer of Lumiphore.
"Using Lumi4®-Tb in the reader technology of our diagnostic tests will provide multiple benefit for Brahms. Thus we will take Lumi4®-Tb into consideration for the development of future analysis systems, both in laboratories and point-of-care-formats," said Ansgar Schmitt, Vice President of Business Development at Brahms. Lumi4®-Tb will both increase sensitivity of Brahms diagnostic tests and allow the development of multiplexed assays (measuring 3-4 parameters in one test sample).
Marco Beckmann, CEO of Nanostart, added: "We congratulate our portfolio company Lumiphore on this major new success in commercialization. The technology from Lumiphore ensures superb quality and reliability of analysis."
About Lumiphore Inc.
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
Based in Richmond, California, Lumiphore Inc, a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide technology for use in high-value applications which are commercialized through market-specific alliances with corporate partners. Lumi4® complexes are a new class of fluorescent-metal lanthanide detection reagents based on technology patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley. Lumi4® is a registered mark of Lumiphore, Inc.
Brahms AG researches, develops, produces and markets innovative diagnostic biomarkers. The company sells its products in more than 65 countries through its own subsidiary companies and sales organizations as well as through its proprietary laboratory systems and global licensing partners.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
For more information, please click here
Dr. Hans Joachim Dürr
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
Copyright © Nanostart AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Designing ultrasound tools with Lego-like proteins August 29th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Meteorite impact on a nano scale August 29th, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016